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The self-renewal efficiency of mouse embryonic stem cells (ESCs) is deter-
mined by the concentration of the transcription factor NANOG. While
NANOG binds thousands of sites in chromatin, the regulatory systems that
control DNA binding are poorly characterised. Here, we show that NANOG
is phosphorylated by casein kinase I, and identify target residues. Phospho-
mimetic substitutions at phosphorylation sites within the homeodomain (S130
and S131) have site-specific functional effects. Phosphomimetic substitution
of S130 abolishes DNA binding by NANOG and eliminates LIF-independent
self-renewal. In contrast, phosphomimetic substitution of S131 enhances LIF-
independent self-renewal, without influencing DNA binding. Modelling the
DNA–homeodomain complex explains the disparate effects of these phospho-
mimetic substitutions. These results indicate how phosphorylation may influ-
ence NANOG homeodomain interactions that underpin ESC self-renewal.
Keywords: casein kinase I; DNA binding; NANOG; phosphorylation;
self-renewal
The patterns of gene expression during development
and cell fate commitment are controlled by a complex
web of sequence-specific transcription factors (TFs).
The ability of TFs to regulate gene expression relies on
their ability to interact with both DNA and protein
partners. Regulation of DNA and partner protein
binding, together with modulation of expression levels,
enables both temporal control and spatial control of
gene expression within a developing organism. One of
the best understood mechanisms for regulating TF
function is via covalent modification of the protein.
These modifications include phosphorylation [1], O-
GlcNAcylation [2], acetylation [3] and ubiquitination
[4]. Examples of regulation of TF function via phos-
phorylation include STAT3, which is translocated into
the nucleus upon phosphorylation [5], c-myb, which is
unable to bind to DNA upon phosphorylation of a
residue N-terminal to the DNA-binding domain [6]
and oestrogen receptor A, which is also blocked from
DNA binding upon phosphorylation [7].
In embryonic stem cells (ESCs), the network of TFs
that underpin self-renewal is centred on the triumvirate
of factors, NANOG, OCT4 and SOX2 that are often
referred to as master transcription factors [8–13].
Amongst these TFs, NANOG has the ability to drive
LIF-independent ESC self-renewal when overexpressed
[8]. In addition to transcriptional interactions between
these TFs [14], each has been shown to be modified
in vivo by covalent modification. For example, various
screens have identified phosphorylated residues in
NANOG, OCT4 and SOX2 [15–18] and phosphoryla-
tion has been reported to modify NANOG protein
Abbreviations
CKI, casein kinase I; TF, transcription factor.
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stability [18,19]. Furthermore, OCT4 and SOX2 are
regulated by O-GlcNAcylation [20] and SOX2 has
been demonstrated to be regulated by acetylation [21].
To investigate how NANOG acts through partner
proteins to deliver function, we determined the
NANOG interactome [22]. This identified > 130 part-
ner proteins of NANOG, including two kinases, one
of which is casein kinase I (CKI). The recent demon-
stration that inhibition of CKI increases reprogram-
ming efficiency of epiblast stem cells [23] suggests that
CKI-mediated phosphorylation is an important regula-
tory mechanism in pluripotent cells. CKI is a widely
expressed enzyme with broad specificity implicated in
diverse processes including regulation of circadian
rhythms, the cell-cycle, cell adhesion and cytoskeletal
structure [24]. CKI also regulates transcription. For
example, CKI regulates the activity of the TFs NFAT-
1 and HIF by direct phosphorylation [25,26], is a criti-
cal component of the b-catenin pathway [27] and regu-
lates p53 activity [28,29]. At sites unprimed by prior
phosphorylation, CKI has a preference for a negative
charge at a position 3 to the target site and an iso-
leucine at +1 (D/E-x-x-S/T-I) [30,31]. In NANOG, 17
of the 61 serine/threonine residues are potential CK1
targets since they either have a negative charge or a
phosphorylatable residue at position 3. Here, we
report that CKI phosphorylates NANOG in vitro,
map sites of phosphorylation and assess the functional
effects of phosphorylation at novel sites in the home-
odomain on NANOG function in ESCs.
Materials and methods
Preparation and phosphorylation of recombinant
NANOG
Recombinant NANOG was prepared as described [32].
Phosphorylation was performed by incubating 2 µg
NANOG with 0.3 U CKI (New England Biolabs, Ipswich,
MA, USA, P6030) in the presence of 200 µM ATP in
reaction buffer (50 mM Tris pH7.5, 10 mM MgCl2, 5 mM
DTT, 0.025% NP-40) at 30 °C for 2 h. The CKI inhibi-
tors triamterene and D4476 were used at final concentra-
tions of 50, 10 and 1 µM. The reaction was stopped by
boiling in Laemmli buffer and the samples loaded onto
SDS/PAGE.
Phosphosite mapping by mass spectrometry
NANOG phosphorylated by CKI was resolved by SDS/
PAGE and stained with colloidal Coomassie. The specific
NANOG band was excised, washed in water and shrunk in
acetonitrile. Gel pieces were reswollen in 50 lL 50 mM
Tris/HCl pH 8.0 and reshrunk in acetonitrile. Gel pieces
were reduced in 50 mM Tris/HCl pH 8.0, 5 mM DTT at
65 °C for 20 min and alkylated in 20 mM iodoacetamide in
50 mM Tris/HCl pH 8.0 at room temperature for 20 min.
Gel pieces were shrunk in acetonitrile, reswollen in 50 mM
triethylammonium bicarbonate and reshrunk in acetonitrile.
Protein was digested from the gel slice using 5 µgmL1
mass spectrometry grade trypsin in 50 mM triethylammo-
nium bicarbonate overnight at 30 °C. The gel was shrunk
by addition of acetonitrile, swollen in 0.1% TFA and pep-
tides extracted twice with acetonitrile. All supernatants
were combined and lyophilised in a SpeedVac prior to mass
spectrometry analysis.
Mass spectrometric analysis was performed by LC-MS-
MS using a linear ion trap-orbitrap hybrid mass spec-
trometer (Orbitrap-Classic, Thermo, Waltham, MA, USA)
equipped with a nanoelectrospray ion source (Thermo)
and coupled to a Proxeon EASY-nLC system. Peptides
(in 0.1% formic acid, 2% acetonitrile) were injected via a
2 cm trap column (Nano Separations, NS-MP-10 Bio-
Sphere C18, 5 lm, 120 A, 360/100 lm) onto a Thermo
(Part No. 160321) Acclaim PepMap100 reverse phase C18
3 lm column (75 lm 9 15 cm) with a flow of
300 nLmin1 and eluted with a 45 min linear gradient of
95% solvent A (2% acetonitrile, 0.1% formic acid in
H2O) to 40% solvent B (90% acetonitrile, 0.08% formic
acid in H2O), followed by a rise to 80% B at 48 min.
The instrument was operated with the ’lock mass’ option
to improve the mass accuracy of precursor ions, and data
were acquired in the data-dependent mode, automatically
switching between MS and MS-MS acquisition. Full scan
spectra (m/z 340–1800) were acquired in the orbitrap with
resolution R = 60 000 at m/z 400 (after accumulation to
an FTMS Full AGC Target; 1 000 000; MSn AGC Tar-
get; 100 000). The 5 most intense ions, above a specified
minimum signal threshold (20 000), based upon a low-res-
olution (R = 15 000) preview of the survey scan, were
fragmented by collision-induced dissociation and recorded
in the linear ion trap (Full AGC Target; 30 000. MSn
AGC Target; 5000). Multistage activation was used to
provide a pseudo-MS3 scan of any parent ions showing a
neutral loss of 48.9885, 32.6570, 24.4942, allowing for 2+,
3+ and 4+ ions, respectively. The resulting pseudo-MS3
scan was automatically combined with the relevant MS2
scan prior to data analysis.
RAW files from the OrbiTrap-Classic were analysed by
Proteome Discoverer 1.4-SP1 (Thermo) using the phosphoRS
[33] node and searched using MASCOT 2.4.1 (www.matrixscie
nce.com) against an in-house database that contained the
NANOG Q80Z64.1 sequence. Searches allowed for variable
modifications; dioxidation (M), oxidation (M), phospho (ST),
phospho (Y) and a fixed modification: carbamidomethyl (C).
Peptide mass tolerance was  10 ppm, and MS2 fragment
mass tolerance was  0.6 Da.
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Cell transfections and self-renewal assays
For episomal assessment of function of NANOG mutants,
DNA was transfected into E14/T cells using Lipofectamine
2000 (Thermo Fisher, 11668027). One million cells were
plated per well of a 6-well plate in 2.0 mL Gmemß/10%
FCS, LIF 30–60 min before DNA addition. 3 lg DNA
was diluted into 250 lL of serum-free Gmemb for each
transfection. Separately, 3 lL of Lipofectamine 2000 was
diluted into 250 lL of serum-free Gmemb and incubated at
room temperature for 5 min before mixing with the DNA
solution and incubation at room temperature for 20 min.
The transfection cocktail was then added to the cells and
the plates rocked gently before being placed in the incuba-
tor. Cells were trypsinised 24 h later, plated at 5 9 104 cells
per 9-cm dish in medium supplemented with 2 lgmL1
puromycin and medium replaced every 2 days. Colonies
were photographed after 12 days following fixation and
alkaline phosphatase staining using a leucocyte alkaline
phosphatase kit (Sigma kit 86-R, St. Louis, MO, USA) [34].
For generation of stable lines, plasmids encoding NANOG
and NANOG mutants were linearised with ScaI and intro-
duced into 44Cre6 NANOG null cells [35] via electropora-
tion. After selection in media containing puromycin, 600 cells
were plated in triplicate in 6-well plates plus and minus LIF.
Plates were stained for alkaline phosphatase as described
above. Antibodies used for determining expression levels are
anti-NANOG, A300-397A, Bethyl Laboratories and anti-
LAMIN B1, Ab16048, Abcam (Cambridge, MA, USA).
Electrophoretic mobility shift assay
All assays used oligonucleotide labelled at the 50 end of the
upper strand with IR700 dye. The DNA probe corresponds
to the NANOG-binding site in Tcf3 promoter
CTGTTAATGGGAGC [36]. Protein was added to
oligonucleotide and buffer to give final concentrations of
10 mM HEPES pH7.9, 10% glycerol, 50 mM KCl, 10 mM
NaCl, 0.4 mM EDTA, 2.5 mM DTT, 0.25% Tween 20,
100 mgmL1 dI:dc, 1 mgmL1 BSA, 10 nM oligonu-
cleotide, 250 nM protein. Reactions were incubated at room
temperature for 30 min before analysis on 5% acrylamide
gels [37]. Data were collected on a LICOR Odyssey Fc.
Recombinant His-tagged homeodomains were expressed in
E. coli with induction of protein expression at 30 °C for
3 h. Bacterial lysates were prepared in 25 mM Tris pH8.0,
500 mM NaCl, 30 mM imidazole and loaded onto His-select
resin (Sigma, P6611). After washing in the same buffer,
protein was eluted in 25 mM Tris pH8.0, 500 mM NaCl,
250 mM imidazole. Proteins were dialysed against 25 mM
Tris pH8.0, 500 mM NaCl and used directly in EMSAs.
Mutagenesis
Synthetic DNAs (IDT) encoding the mutations were inserted
into pPyCAG-NANOG [8] cut with PpuMI and NotI.
Chromatin immunoprecipitation
Ten million E14Tg2a cells were resuspended in 3 mL
GMEM/FCS (10%) and cross-linked with 1% formalde-
hyde (Sigma, P6611) for 10 min at room temperature. The
reaction was quenched with 0.125 mM glycine for 5 min at
room temperature. Cells were pelleted and washed twice
with cold PBS. Cells were resuspended in 300 lL of swel-
ling buffer (5 mM Pipes pH 8, 85 mM KCl) supplemented
with 19 protease inhibitor cocktail (Roche) and 0.5% NP-
40. The suspension was incubated for 20 min on ice. Nuclei
were pelleted and resuspended in 1.5 mL of 0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris/HCl pH8, 150 mM
NaCl, supplemented with 19 protease inhibitor cocktail.
Samples were sonicated at 4 °C in a Bioruptor (Diagen-
ode). 20 lg of sonicated chromatin was used per ChIP.
Immunoprecipitation with 5 µg rabbit anti-NANOG [32]
was performed overnight with rotation at 4 °C, in a final
volume of 1 mL. Immunocomplexes were purified using
Protein-G Dynabeads (Lifetech, Waltham, MA, USA).
Washing and elution were as described in Ref. [38]. The
sequences of the oligos used for ChIP-Q-PCR are as fol-
lows: Xin1: AACCCTTTTAAGTCCACTGTAAATTCC
and TAGAGAGCCAGACAATGCTAAGCC; Xex1b:
CATCAGGCTTGGCAGCAA and TTCATCAGCAATG
TCATATCAAACA; EE2: TGCTGGTGGTATTCAAC
TGC and CGGATCTGTGGAATTCGTG; E7: TAAGG
GACACCTCCCTAGCC and CCATACCCCACACACCA
TGT; Otx2 A: CAAGAACAAAACCCCACGCC and
GTGCCAGCCAATGAGTCCTA; Otx2 B: GTGGAAGG
GCGTCTAGAAGG and GCAGTCAATGGGCTGAG
TCT [39].
Modelling a mouse NANOG homeodomain–DNA
structure
NANOG homeodomain sequences from mouse and human
were aligned with ClustalOmega [40]. The coordinates of
protein chain A from the mouse NANOG homeodomain
crystal structure (PDBID: 2VI6) were renumbered and
superimposed on chain A of the human NANOG HD
cocrystal structure with DNA (PDBID: 4RBO) with
SUPERPOSE in the CCP4 software suite [41]. The side
chains of serines 130 and 131 were phosphorylated, and the
structures were visualised with PYMOL (Schrodinger Inc,
New York, NY, USA).
Results
NANOG is phosphorylated by casein kinase I at
multiple sites
The presence of CKI in the NANOG interactome [22]
combined with the potential of kinases to modulate
the function of TFs [5–7] led us to investigate whether
3FEBS Letters (2020) ª 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
N. P. Mullin et al. Casein kinase I regulation of NANOG
CKI could modulate NANOG function by phosphory-
lation. Recombinant NANOG was therefore incubated
with recombinant active CKI and ATP in vitro. This
resulted in a clear shift in molecular weight of
NANOG, which can be indicative of one or more
phosphorylation events (Fig. 1A). The shift in mobility
was inhibited by inclusion of either of the CKI inhibi-
tors triamterene or D4476, suggesting that retarded
electrophoretic mobility is indeed a result of NANOG
phosphorylation by CKI. The greater degree of inhibi-
tion by D4476 is consistent with the lower IC50 of
CKI inhibition by D4476 (0.3 µM) compared to tri-
amterene (6.9 µM) [42,43].
To identify phosphorylation sites, NANOG was
incubated with CKI and ATP, subjected to SDS/
PAGE and the stained bands analysed by mass spec-
trometry. Three phosphorylated peptides were detected
(Fig. 1B and Table 1), two in the N-terminal domain
and one in the homeodomain. The most N-terminal
phosphorylated peptide was detected in singly and
doubly phosphorylated forms. The single phosphoryla-
tion is on either serine 56 or 57, with the mass spec-
trometry data indicating an equal probability of
phosphorylation on each residue. The doubly phos-
phorylated form is also phosphorylated on either ser-
ine 56 or 57. In addition, the doubly phosphorylated
form is likely to be modified on either serine 68 or 69,
although there is also a low probability that this sec-
ond phosphorylation could occur on either threonine
70 or even serine 71 (Table 1). The second phosphory-
lated N-terminal peptide contains a single modification
that is likely to be on serine 77, although the mass
spectrometry data indicate a 10% probability that ser-
ine 78 could be phosphorylated. These results are con-
sistent with previous work showing that NANOG
expressed in 293T cells is phosphorylated on either ser-
ine 56 or 57 and either serine 77 or 78 [19]. The third
phosphopeptide is derived from the homeodomain.
The mass spectrometry data suggest that the modified
residue is likely to be serine 131. Notably, S131 is a
good match to the consensus CKI sequence (D/E-x-x-
S/T-I), since residue 128 is a glutamate and residue
132 is an isoleucine [30,31]. However, the possibility
that serine 130 is phosphorylated cannot be dis-
counted. S130 and S131 correspond to residues 35 and
36 in the canonical homeodomain numbering system
[44]. Therefore, the phosphorylation sites identified
here by mass spectrometry include residues previously
reported as phosphorylation sites [19,45,46] as well as
novel sites of phosphorylation within the home-
odomain; these are highlighted on a domain diagram
of NANOG (Fig. 1B).
Nanog + CK1 + ATP
Triamterene D4476
B                  
ND HD WRCD1 CD2
A
 0      1     10    50    1     10     50   concentration (μM)
Fig. 1. NANOG is phosphorylated by
casein kinase I. (A) Immunoblot of
recombinant NANOG incubated with CKI
and ATP in 0, 1, 10 or 50 µMtriamterene or
D4476. (B) Domain diagram of NANOG
with phosphorylation sites identified by
mass spectrometry marked as stars. ND –
N-terminal domain, HD – homeodomain,
CD1 – C-terminal domain 1, WR –
tryptophan repeat, CD2 – C-terminal
domain 2. Sequences of phosphorylated
NANOG peptides are shown with potential
phosphorylation sites highlighted. For all
peptides, NANOG residue numbering is
shown above the sequence. For the
homeodomain-derived peptide, the
canonical homeodomain numbering is
shown below the sequence.
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Mutagenesis of phosphorylation sites within the
NANOG homeodomain
The identification of CKI-mediated phosphorylation
within the NANOG DNA-binding domain suggests
that these modifications may regulate NANOG func-
tion. To test for possible roles of phosphorylation, the
two potential phosphorylation sites within the home-
odomain were mutated simultaneously, either to ala-
nine or to the phosphomimetic residue aspartate. In
addition, both residues were individually mutated to
aspartate. To determine whether these mutations
affected the defining capacity of NANOG to confer
LIF-independent self-renewal on transfected ESCs [8],
these mutants were cloned into constitutive episomal
expression plasmids and transfected into E14/T ESCs
to rapidly assess ESC self-renewal (Fig. 2A,B). Exam-
ples of colony morphologies containing undifferenti-
ated ES cells, differentiated cells or a mix of both are
shown in Fig. 2B. Mutagenesis of both residues to ala-
nine has little effect on the ability of NANOG to con-
fer LIF-independent self-renewal. However,
mutagenesis to aspartate either singly or doubly has a
marked effect. Substitution of S130 by aspartate
(S130D) abolishes the LIF-independent self-renewal
function of NANOG. Moreover, in the presence of
LIF, S130D acts as a dominant interfering mutant
since self-renewal is decreased below the level obtained
by transfection of an empty vector control. In con-
trast, a phosphomimetic at position 131 increases the
number of self-renewing colonies formed in either the
presence or absence of LIF (Fig. 2B and Fig. S1A,B).
To attempt to verify the findings from E14/T ESCs,
and to further investigate the effect of mutating serine
130 and 131, stably expressing ESC lines were gener-
ated in a Nanog/ background [35] and the ability of
the mutants to confer LIF-independent self-renewal
assayed (Fig. 3). Immunoblot analysis indicated that
the stable cells express comparable levels of NANOG
(Fig. 3A). Consistent with the clonal self-renewal
results from E14/T cells, S131D increases self-renewal
efficiency in the presence and absence of LIF whereas
S130D decreases self-renewal efficiency (Fig. 3B).
Notably, the dominant-negative effect of S130D
observed in E14/T ESCs is not observed in a Nanog/
 background, consistent with the mutant protein
interfering with WT NANOG function. These data
suggest that individual phosphorylation at the adjacent
sites 130 and 131 has opposite effects on the biological
activity of NANOG. Mimicking phosphorylation at
130 abrogates NANOG function, and in wild-type
cells interferes with the function of endogenous
NANOG. In contrast, mimicking phosphorylation at
131 enhances both the total number and the propor-
tion of cells that undergo efficient self-renewal.
DNA-binding properties of mutants
As S130 and S131 are in the NANOG homeodomain,
their phosphorylation may alter the ability of
NANOG to bind DNA. To compare the abilities of
NANOG mutants to bind DNA, recombinant home-
odomains encompassing the D > A mutations were
purified for use in electrophoretic mobility shift assays
(EMSAs; Fig. 4A). While the S131D homeodomain
has a DNA-binding capacity similar to that of the
wild-type NANOG homeodomain, EMSAs indicate
that the DNA-binding capacity of S130D home-
odomain is severely impaired (Fig. 4B).
To investigate the ability of NANOG mutants to
bind to chromatin, ChIP was performed using the
Table 1. Identification of NANOG sites phosphorylated by CK1 using mass spectrometry.
Peptide sequencea Phos sites M/Z (Da) Ion score phosphoRS probabilities33
55-PSSEDLPLQGSPDSSTSPK-73 1 1004.9417 59 S56:50.0
S57:50.0
55-PSSEDLPLQGSPDSSTSPK-73 2 1044.9257 38 S56:50.0
S57:50.0
S68:47.5
S69:47.5
T70:4.5
S71:0.5
74-QKLSSPEADKGPEEEENK-91 1 698.9794 39 S77:90.0
S78:10.0
120-YLSLQQMQELSSILNLSYK-138 1 780.0541 30 S130:8.9
S131:91.1
aSequences are numbered according to the primary NANOG sequence.
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stable lines described above. Mutation of S131 to
aspartate has little effect on the ability of NANOG to
bind chromatin (Fig. 4C). However, S130D was not
localised to chromatin at any of the three loci assayed.
This is in agreement with the reduced capacity of
S130D to bind DNA in vitro (Fig. 4B). Together these
data indicate that while phosphorylation of NANOG
on S131 has no effect on DNA binding, phosphoryla-
tion of S130 may disrupt the binding of NANOG to
target sites in chromatin.
Modelling of the NANOG homeodomain–DNA
complex
The differing effects observed between mutating S130
and S131 on DNA and chromatin binding are
intriguing, given that the residues are adjacent in the
primary NANOG sequence. While no three-dimen-
sional structure is available for mouse NANOG in
complex with DNA, the tertiary structure of the
mouse homeodomain has been solved [36], as has the
structure of the human homeodomain in complex with
DNA [47]. An alignment of the mouse and human
NANOG homeodomains (Fig. 5A) was used to con-
struct a three-dimensional model of mouse NANOG
in complex with DNA (Fig. 5B). The root mean
square deviation of superposed mouse and human
NANOG HD chains was 0.91 A over all atoms. High-
lighted on the model are S130 and S131, which are
present at the C-terminal end of homeodomain a-helix
2. This shows that neither S130 nor S131 are in direct
contact with DNA (Fig. 5B). A three-dimensional
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Fig. 2. Self-renewal assays of E14/T cells
transfected with NANOG variants. (A) E14/
T ESCs were transfected with pPyCAGIP
plasmids encoding the indicated NANOG
mutants and cultured in media containing
puromycin in the presence or absence of
LIF (EV, empty vector; WT, wild-type
NANOG). After 12 days, plates were
stained for alkaline phosphatase activity.
Assays were performed in triplicate. (B)
Left, Quantitative assessment of colony
morphologies from (A) determined in the
presence or absence of LIF. Data shown
are from a single experiment (data and
error bars are the means and standard
deviations, respectively, from three
technical replicates) and are representative
of three independent biological replicates.
Biological replicates are shown in Fig.S1.
Right, examples of colony morphologies
containing undifferentiated ES cells,
differentiated cells or a mix of both.
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model of mouse NANOG in complex with DNA was
also prepared after addition of a phosphate group to
either S130 or S131 (Fig. 5C). Mutation of S130 to
aspartate creates steric clashes with Tyr 137 and Val
140 at the N terminus of a-helix 3 (or in an alternative
rotamer conformation with backbone atoms of Leu
135 and Ser 136; Fig. 5D,E). The phosphorylation of
Ser 130 is therefore likely to lead to a change in the
position or orientation of at least the N-terminal end
of a-helix 3, which may interfere with DNA binding.
In particular, the critical contacts made with the DNA
backbone by Tyr 137 at the N-terminal end of this
helix are likely to be disrupted. In contrast to S130,
the side chain of S131 faces away from helix 3, making
it unlikely that phosphorylation of this residue would
directly influence DNA binding. This is consistent with
the EMSA and ChIP results showing that S131D
retains the ability to bind DNA and to localise to
NANOG target sites in chromatin (Fig. 4B,C).
Discussion
The NANOG interactome contains more than 130
proteins of which only two are kinases (casein kinases
I and II) [22]. A role for CKI in pluripotent cells was
recently reported, with the demonstration that CKI
inhibition improved the efficiency of reprogramming
of epiblast stem cells to ESCs [23,42]. To further inves-
tigate CKI function in ESCs, the ability of CKI to
directly phosphorylate NANOG, one of the central
members of the pluripotency gene regulatory network,
was investigated. This showed that NANOG is a CKI
substrate in vitro. Of the sites we identify as phospho-
rylated by CKI, residues 70 and 131 are previously
unreported phosphorylation sites that each have a neg-
atively charged residue at position 3 that fits the D/
E-x-x-S/T consensus for CKI phosphorylation [30,31].
Of the remaining sites, residues 68 and 71 have serines
at the 3 position which could act as priming sites
in vivo. Consistent with this possibility, serine 65 has
been reported to be phosphorylated in cells [19,45].
The probability of serine 71 being phosphorylated by
CKI is low (Table 1), and furthermore, there has been
no in vivo identification of a potential priming phos-
phorylation on serine 68. We also identified additional
CKI sites that have been reported as sites of phospho-
rylation. Specifically, phosphorylation of mouse
NANOG at S56/S57 has been demonstrated in ESCs
and in 293T cells [19,45]. In addition, protein kinase A
can phosphorylate recombinant human NANOG on
the residue equivalent to S78 in mouse NANOG [46].
However, these latter sites do not match the consensus
for CKI phosphorylation. Moreover, functional roles
have not been assigned to any of the above phospho-
rylated residues. Interestingly, previous studies have
not reported phosphorylation within the NANOG
homeodomain. Our work identifies a novel phosphory-
lation site(s) within the homeodomain which could
potentially occur on S130 and/or S131 (corresponding
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Fig. 3. Self-renewal assays ofNANOGnull ESCs rescued with
NANOG variants. (A)NANOG/ESCs (44cre6) were electroporated
with linearised pPyCAGIP plasmids encoding the indicated NANOG
mutants and selected in puromycin LIF (EV, empty vector; WT,
wild-type NANOG). After expansion, cell extracts were assayed for
expression level by immunoblotting. (B) Quantitative assessment
of colony morphologies of stably expressing lines from (A) plated
at clonal density in the presence or absence of LIF and stained for
alkaline phosphatase activity after 6 days. Data and error bars are
the means and standard deviations, respectively, of three
independent experiments. Significance of variation from WT
*P < 0.1, **P < 0.05 and n/s – not significant (Student’st-test).
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to residues 35 and 36 in the canonical homeodomain
numbering system [44]).
Intriguingly, phosphorylation of residues within
other homeodomains has functional consequences. For
example, phosphorylation of PRH at a serine immedi-
ately before the start of helix 3 of the homeodomain
(residue 41 of the HD numbering scheme) decreases
DNA binding [48]. Structural modelling suggests this
is due to a disruption of the side chain interactions
that mediate DNA binding [49]. This is interesting rel-
ative to our study, since the phosphate group added to
residue 41 of the PRH HD is in a 3D space close to
that occupied by introduction of a phosphate group to
homeodomain residue 35 (S130) of NANOG. Of fur-
ther note, mimicking phosphorylation of NANOG
HD residue 35 reduces DNA binding and abolishes
the biological activity of NANOG, echoing the effect
of mimicking phosphorylation at PRH HD residue 41
on abolition of activity in vivo [48]. In contrast, phos-
phorylation within homeodomains can also increase
DNA affinity. This is the case for Nkx2.5, where phos-
phorylation of a residue between the first and second
helices of the homeodomain increases affinity for
DNA and is also important for transcriptional activity
[50]. Phosphorylation of homeodomains can also have
functional consequences without affecting DNA
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Fig. 4. DNA binding by NANOG mutants.
(A) SDS/PAGE of purified homeodomains
expressed inE. coli.(B) EMSAs with
recombinant homeodomains performed
using a probe corresponding to the
NANOG-binding site within theTcf3locus
[36]. (C) ChIP-PCR of NANOG at known
binding sites. ChIP was performed with
NANOG antibody using the stable
populations described in Fig. 3. Three
known NANOG-binding sites withinXist,
EsrrbandOtx2were assessed; regions
within the same genes which do not bind
NANOG provided negative controls. The
positive binding regions (Xin1, EE2 and
Otx2 A) are diagrammed below each gene
and negative control regions (Xex1b, E7
and Otx2 B) above each gene. Data are
mean of three replicates. Error bars are
standard deviation. *P < 0.05, n/s – not
significant.
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binding. For example, Ftz can be phosphorylated by
protein kinase A on a threonine in the first helix of the
homeodomain. Substitution of threonine with alanine
does not affect DNA binding but fails to rescue the
segmentation defect in ftz null drosophila embryos
[51].
Mass spectrometry identified a singly phosphory-
lated residue in the NANOG peptide covering serines
130 and 131. While it is possible that NANOG could
either be phosphorylated on 130 or 131, probability
analysis of the mass spectrometry data suggests that
phosphorylation of residue 131 is the more likely.
Moreover, it is notable that phosphorylation at S131
is consistent with studies of CKI specificity, since the
residue at 3 is a glutamate and the residue at +1 is
an isoleucine [30,31]. Nevertheless, to obtain compre-
hensive insight into the potential functional conse-
quences of phosphorylation of either of these residues,
we mimicked phosphorylation by mutagenesis of seri-
nes to aspartate. Intriguingly, aspartate substitution of
either S130 or S131 of NANOG had functionally dis-
tinct effects. Similar to the effect of phosphorylation
of S41 within the PRH homeodomain [48], aspartate
substitution of S130 reduces the capacity of NANOG
to bind DNA. Consistent with this loss of DNA-bind-
ing activity, S130D showed a loss of ESC self-renewal
capacity. Moreover, the modelled structure of a
NANOG–DNA complex shows that phosphorylation
of S130 would cause steric hindrance to the spatial dis-
position of residues L135, S136, Y137 and V140 (HD
residues 40, 41, 42 and 45). Notably, this would
include interference with the critical contacts between
the DNA backbone and Y137. Alanine substitution of
Y137 decreases DNA binding activity [47] and impairs
the reprogramming activity of mouse NANOG [52].
These contact disruptions differ in detail to those seen
in PRH, where phosphorylation of S41 disrupts a
hydrogen bonding network centred on Q44.
In contrast, aspartate substitution of S131 increased
the ESC self-renewal capacity of NANOG without
Fig. 5. Model of mouse NANOG
homeodomain in complex with DNA. (A)
Alignment of the homeodomain (HD)
sequences of mouse (amino acids 94–155)
and human NANOG (93–155). White
letters on red background indicate
conserved amino acids; red letters on
white background indicate similar amino
acids. Two potential phosphorylation sites,
S130 and S131, are highlighted with stars.
Secondary structure elements of the
mouse NANOG HD crystal structure
(PDBID:2VI6) and the human NANOG HD
cocrystal structure with DNA
(PDBID:4RBO) are shown above and
below the alignment, respectively. (B)
Structural model of mouse NANOG HD
bound toOCT4promoter DNA, based on
the human NANOG HD:DNA cocrystal
structure. Four amino acids in a-helix 3
that contact DNA (Y137, K138, N146,
R148) are shown as sticks, along with
S130 and S131 (purple). (C) Structural
model of mouse NANOG HD,
phosphorylated at S130 (S130-P) and S131
(S131-P), bound toOCT4promoter DNA.
Phosphorylation of S130 introduces steric
clashes with the amino acid residues
shown in blue (L135, S136, Y137, V140)
sticks. (D, E) Expanded view of region
around S130. Atoms of Y137 and Ser130/
pSer130 are shown as spheres
representing van der Waal radii. Residues
in blue as per C.
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affecting DNA binding. The results from self-renewal
assays demonstrate that a phosphomimetic at position
131 has a large effect on NANOG function, increasing
its ability to support LIF-independent self-renewal sev-
eral fold. It will be interesting in future to see whether
S131D also enhances reprogramming to an ES cell
state [52–54]. In the model of the NANOG–DNA
complex, the side chain of serine 131 points away from
the DNA. This is consistent with the lack of an effect
on DNA binding for S131D as assayed by EMSA.
Therefore, instead of mediating protein–DNA interac-
tions S131 may mediate interaction with NANOG
partner proteins. Although NANOG is known to
interact with > 130 partner proteins [22,55,56], the resi-
dues within NANOG that mediate these interactions
have been identified in only a minority of cases [22,57].
The fact that modification of S131 results in an
increase in activity that is independent of DNA bind-
ing suggests that reversible modification of the
NANOG homeodomain may be used as a switch to
regulate interactions between NANOG and partner
proteins and to thereby modulate ESC self-renewal
efficiency. Future work should address this issue and
the alternative possibility that S131D affects protein
stability as is the case for the SOX17 gain-of-function
mutant SOX17 V118M [58].
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